IP Library › Granted Patent US 11,538,580
Granted Patent B2
US 11,538,580 · App. 15/880,692 · Granted Dec 27, 2022

Method and system for providing basal profile modification in analyte monitoring and management systems

Inventors: Mark Kent Sloan (Redwood City, CA); Gary Alan Hayter (Oakland, CA)
Assignee: Abbott Diabetes Care Inc.
G16H40/67A61B5/14532A61B5/4839A61M5/1723G16H10/40G16H10/60G16H20/17G16Z99/00A61B2560/0223A61M2205/3303A61M2205/52A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,538,580
App. No.
15/880,692
Granted
Dec 27, 2022
Kind
B2
Abstract

Method and system for providing basal profile modification in insulin therapy for use with infusion devices includes periodically monitoring the analyte levels of a patient for a predetermined period of time in order to determine, based on the monitored analyte levels, an appropriate modification factor to be incorporated into the underlying basal profile which was running at the time the periodic monitoring of the analyte levels were performed.

Claims (42)

1. A method, comprising:

retrieving a current drug therapy profile of a user;

monitoring, using a continuous in vivo analyte monitoring unit, a continuous, in vivo analyte level of the user for a predetermined period of time during which a medication is administered to the user according to the current drug therapy profile;

retrieving a predetermined parameter, wherein the predetermined parameter comprises an iterative loop gain factor;

determining a modification to the current drug therapy profile based on the monitored analyte level and the predetermined parameter during the predetermined period of time; and

adjusting a drug dosage or rate for administration by a drug delivery device based at least on the modification to the current drug therapy profile.

2. The method of claim 1 , wherein the iterative loop gain factor is set for dampened control.

3. The method of claim 1 , wherein the iterative loop gain factor is set for critical control.

4. The method of claim 1 , wherein the iterative loop gain factor is set for over control.

5. The method of claim 1 , wherein the modification to the current drug therapy profile based on the iterative loop gain factor provides for reducing one or more analyte excursions in which the analyte level exceeds a predetermined analyte level.

6. The method of claim 1 , wherein the analyte is glucose.

7. The method of claim 1 , further comprising retrieving one or more additional predetermined parameters, wherein the one or more additional predetermined parameters comprise insulin sensitivity, a drug infusion rate, a drug infusion time period, a time period corresponding to the monitored analyte level, or a time of day associated with the monitored analyte level.

8. The method of claim 1 , wherein the current drug therapy profile is an insulin infusion profile.

9. The method of claim 1 , wherein the iterative loop gain factor is based on at least one prior modification to the current drug therapy profile.

10. The method of claim 1 , wherein the modification is calculated as a product of the iterative loop gain factor and a difference between the monitored analyte level and a target analyte level.

11. The method of claim 1 , wherein the predetermined period of time comprises one or more days.

12. The method of claim 1 , wherein the iterative loop gain factor is less than 1.

13. A system, comprising:

a continuous, in vivo analyte monitoring unit; and

a processing unit operatively coupled to the in vivo analyte monitoring unit, the processing unit configured to:

retrieve a current drug therapy profile of a user:

receive a plurality of monitored analyte levels of the user for a predetermined period of time during which a medication is administered to the user according to the current drug therapy profile;

retrieve a predetermined parameter, wherein the predetermined parameter comprises an iterative loop gain factor;

determine a modification to the current drug therapy profile based on the received plurality of monitored analyte levels and the predetermined parameter during the predetermined period of time; and

adjust a drug dosage or rate for administration by a drug delivery device based at least on the modification to the current drug therapy profile.

14. The system of claim 13 , wherein the iterative loop gain factor is set for dampened control.

15. The system of claim 13 , wherein the iterative loop gain factor is set for critical control.

16. The system of claim 13 , wherein the iterative loop gain factor is set for over control.

17. The system of claim 13 , wherein the modification to the current drug therapy profile based on the iterative loop gain factor provides for reducing one or more analyte excursions.

18. The system of claim 13 , wherein the analyte monitoring unit comprises a sensor unit in fluid contact with the analyte of the user.

19. The system of claim 13 , wherein the processing unit is operatively coupled to the drug delivery device.

20. The system of claim 13 , wherein the iterative loop gain factor is based on at least one prior modification to the current drug therapy profile.

21. A system, comprising:

a continuous, in vivo glucose monitoring unit; and

a processing unit operatively coupled to the in vivo glucose monitoring unit, the processing unit configured to:

retrieve a current insulin therapy profile of a user;

receive a plurality of monitored glucose levels of the user for a predetermined period of time during which insulin is administered to the user according to the current insulin therapy profile;

retrieve a predetermined parameter, wherein the predetermined parameter comprises an iterative loop gain factor;

determine a modification to the current insulin therapy profile based on the received plurality of monitored glucose levels and the predetermined parameter during the predetermined period of time; and

recommend the modification to the current insulin therapy profile to the user; and

an insulin delivery device unit configured to treat the user based on at least the modification to the current drug therapy profile, wherein treating the user comprises administering and/or adjusting based at least on the modification to the current drug therapy profile: an insulin dosage, an insulin rate, or any combination thereof.

22. The system of claim 21 , wherein the iterative loop gain factor is based on at least one prior modification to the current drug therapy profile.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2018
From: SLOAN, MARK K.; HAYTER, GARY
To: ABBOTT DIABETES CARE INC.
Reel/Frame 046755/0527 →
Continuity (6)
Continuation 15613713 · Jun 5, 2017
Continuation 15071610 · Mar 16, 2016
Continuation 14081737 · Nov 15, 2013
Continuation 12833975 · Jul 10, 2010
Continuation 11267724 · Nov 4, 2005
Related Publication 20180289892A1 · Oct 11, 2018
Cited By (2)
US 12,329,490 US 12,725,702